Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

2.560 -0.170 (-6.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 Next >
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
From INmune Bio, Inc.
Via GlobeNewswire
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge?
Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday. 
Via Benzinga
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
From INmune Bio, Inc.
Via GlobeNewswire
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. 
Via Benzinga
Which stocks have an unusual volume on Thursday?
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Crude Oil Moves Lower; Joby Aviation Shares Surge
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Which stocks are moving on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain
INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint. 
Via Benzinga
Dow Gains Over 100 Points; Chicago PMI Weakens In June
 
Via Benzinga
Topics Stocks
Gapping stocks in Monday's session
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial
The primary endpoint of the study was not met in the intent-to-treat population, the company said. 
Via Stocktwits
Get insights into the top gainers and losers of Monday's pre-market session.
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes
INmune Bio stock rose sharply on high volume ahead of topline Phase 2 trial data for XPro in early Alzheimer's, expected on June 30. 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week
INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.